Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $53.9 million.

  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average) fell 13.32% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year decrease of 13.32%. This contributed to the annual value of $53.9 million for FY2024, which is 12.75% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Shares Outstanding (Weighted Average) of $53.9 million as of FY2024, which was down 12.75% from $61.8 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) registered a high of $61.8 million during FY2023, and its lowest value of $27.5 million during FY2020.
  • Over the past 3 years, Fulcrum Therapeutics' median Shares Outstanding (Weighted Average) value was $53.9 million (recorded in 2024), while the average stood at $55.9 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) surged by 47.65% in 2021, and later fell by 12.75% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $27.5 million in 2020, then surged by 47.65% to $40.5 million in 2021, then grew by 28.37% to $52.1 million in 2022, then increased by 18.77% to $61.8 million in 2023, then dropped by 12.75% to $53.9 million in 2024.